BACKGROUND: Sibutramine, an inhibitor of serotonin and noradrenaline uptake, reduces appetite to cause weight loss. This study tested the hypothesis that an increase in energy expenditure also contributes to this weight loss. In addition, the effects of sibutramine on adrenaline induced changes in heart rate and cardiac output were determined METHODS: Nineteen obese females randomly received either sibutramine 15 mg daily or placebo for 12 weeks along with dietary advice. Resting energy expenditure (REE) was measured and then energy expenditure was measured during a 30 min infusion of adrenaline (25 ngaminakg IBW). Cardiac output and heart rate, measured by Duplex Colour Doppler ultrasonography, were similarly measured in the basal state and post adrenaline. All measurements were recorded at baseline and then after 12 weeks. RESULTS: Ten patients who received sibutramine reduced their weight by 8.1 AE 3.8% while 9 placebo treated subjects reduced their weight by 5.1 AE 4.4%, P 0.13. In absolute terms, REE decreased in placebo subjects from 1500 AE 201 kcala24 h to 1357 AE 231 kcala24 h (9.4 AE 9.9%) and in sibutramine subjects from 1540 AE 184 kcala24 h to 1444 AE 128 kcala24 h (5.3 AE 12.0%), P 0.77. The increased weight loss in the sibutramine group was associated with an increase in the FFM adjusted REE (2.2 AE 16.1%) unlike the expected decrease (5.8 AE 9.5%) in the placebo group (P 0.11). There was some suggestion (P 0.09) that the usual positive correlation between loss of weight and decline in REE was lost in the sibutramine group (r 7 0.30) compared with placebo (r 0.35). There was a negative correlation between loss of FFM and decline in REEakg FFM and (P 0.029) which was not evident in placebo (P 0.83). Adrenaline induced energy expenditure was similar in the two groups at the end of the 12 week period and there were no signi®cant cardiovascular changes between the two groups. CONCLUSIONS: Sibutramine limits the decline in REE associated with weight loss, equivalent to about 100 kcalad. This could allow greater numbers of people to maintain a greater degree of weight loss.
Introduction
Obesity is an increasing public health issue, and a major contributor to several diseases. Long term response to dietary restriction is poor and the medical consequences expensive, which has focused increasing effort on pharmacological therapy.
Sibutramine is an inhibitor of serotonin and noradrenaline reuptake which has been developed as an energy balance regulator with the potential to modify both energy intake and output in the management of obesity. Sibutramine produces dose-related weight loss, when administered at 5 ± 30 mg per day, with optimal doses of 10 ± 15 mg per day. 1 This weight loss is thought to result from its hypothalamic SNRI actions combining to promote satiety. However, sibutramine has also been shown to elevate non-shivering thermogenesis in rats, by using energy through promoting uncoupled oxidation of nutrients. 2 Such a mechanism could augment loss of weight by opposing the decline in metabolic rate which occurs with weight loss and which limits the weight loss that can be maintained.
This study investigates whether sibutramine contributes to weight loss in humans by increasing resting energy expenditure, by blocking the adaptive reduction in REE that occurs with loss of weight, or by increasing the thermogenic response to a standard challenge. Experimentally, thermogenesis can be stimulated by food, glucose, cold exposure and catecholamines. In experimental animals, noradrenaline is the dominant circulating catecholamine, but in humans adrenally derived adrenaline is the major mediator. We investigated the thermogenic, blood pressure, pulse and cardiac output response to a standard adrenaline infusion in subjects on sibutramine or placebo for a 12 week period.
Methods

Subjects
Nineteen female subjects were recruited by local advertisement as part of an experimental weight loss programme. Ethical permission was granted by the Glasgow Royal In®rmary Ethics Committee. Written informed consent was obtained and no payment or inducement was offered. Inclusion criteria were age 18 ± 65 and body mass index 30 ± 44 kgam 2 ). Exclusion criteria were diastolic blood pressure greater than 95 mmHg; resting heart rate greater than 100 beats per minute; unstabilised (`3 months) antihypertensive therapy; obesity of an endocrine origin; presence of any other signi®cant medical illness; subjects taking anorectic agents, laxatives or other medications which might alter body weight. Diuretic and thyroid preparations were permitted if stabilised for 3 and 6 months respectively prior to study. Diabetes; subjects who had lost more than 3 kg in the previous three months; pregnancy or risk of pregnancy were also exclusion criteria. Pregnancy tests were carried out on recruitment to the study.
Protocol
The study design was a double-blind, placebocontrolled, randomised trial of sibutramine 15 mg daily or placebo for a 12 week period. The study medication was taken in the morning prior to breakfast. All subjects received dietary counselling for a diet of 30% fat and energy content set at 600 kcalad less than their estimated requirements (BMRÂ 1.4 7 600 kcal). They were provided with personalised diet sheets and advised how to use them. This approach should, given 100% compliance, lead to weight loss of approximately 7 ± 8 kg over 12 weeks in each subject. All measurements were performed prior to commencing the medication, and repeated at the end of the 12 week period. Subjects were seen at interim periods of 4 and 8 weeks to check compliance with medication and diet and to detect adverse events.
Measurements
Body morphology. Height was measured with the subject standing, back to a stadiometer, in bare feet, to the nearest 1.0 mm. Weight was measured to the nearest 100 g using a beam balance, with the patient in indoor clothing and without shoes. The subjects were weighed in the fasting state with an empty bladder. Waist circumference was measured midway between the levels of the lowest ribs and the iliac crest and hip circumference was measured at the level of the greater trochanters using an inelastic tape. Body fat mass and percentage body fat were calculated from waist circumference and age using standard equations. 3 The equation for body fat % (0.439Âwaist) (0.221Âage) 7 9.4, which was the most predictive for obese females in the validation study. 3 Laboratory. Fasting blood samples were taken on ice, centrifuged immediately and then stored at 7 70 C prior to batch assay. Plasma adrenaline concentrations were determined by high performance liquid chromatography with electrochemical detection. 4 Plasma glucose was measured using an automated glucose oxidase method (normal range, 4.0 ± 5.5 mmolaL). Plasma insulin was measured using a two-site immuno-radiometric method (normal range 0 ± 13 mUaL).
Ultrasound. Cardiac output measurement was performed by one of two observers using an ATL Ultramark 9 system. The ascending aorta was successfully visualised from the suprasternal notch in most subjects. Having visualised the ascending aorta along its longitudinal axis, a Doppler sonogram was obtained from within the full width of the vessel. This sonogram was then analysed using the ultrasound system software, giving a value for mean blood velocity across the vessel diameter and over several cardiac cycles (Time Averaged Mean Velocity or TAMV). The vessel was then imaged in the transverse plane, allowing measurement of its cross-sectional area. Three sets of TAMV and cross-sectional area measurements were taken at each assessment. Blood volume ±¯ow rates were then obtained by multiplying together means for TAMV and area. This technique has previously been validated in terms of comparison with other techniques used to measure cardiac output 5, 6 and in terms of reproducibility. 7 Energy expenditure. Energy expenditure and respiratory quotient were measured by ventilatedhood indirect calorimetry (Deltatrac, TM Datex, Helsinki, Finland), using a computerised¯ow-through, canopy-gas analyser system, which was calibrated with precision gas mixture before each measurement. Validation of the system was performed periodically using the ethanol combustion method according to manufacturer's instructions. REE was calculated according to Ferranini 8 and expressed as kcala24 h.
Study procedure. Studies took place in a temperature-controlled room (23 ± 25 C) in the morning, after subjects had fasted from the night before. On arrival, subjects rested supine. For blood sampling, a 20-gauge cannula (Vygon Biovalve) was inserted retrogradely into a vein on the dorsum of the hand. This hand was placed in a hand-warming box (50 ± 60 C) for 20 min to obtain`arterialised' venous blood samples. 9 Blood samples were withdrawn via a three-way tap. A second cannula was inserted in the contralateral antecubital vein for later infusion of adrenaline.
When the subject was relaxed, after lying quietly for 15 min, resting energy expenditure (kcala24 h) and basal respiratory quotient (RQ) were measured over Results from the ®nal 15 min were averaged. Baseline ultrasonography was then performed. Next, an ECG monitor was attached to monitor heart rate and rhythm. Brachial arterial blood pressure recorded manually every 10 min. The ®rst audible sound was taken to denote systolic blood pressure with Korotkoff phase 5 taken to denote diastolic blood pressure.
An adrenaline infusion was commenced at a rate of 25 ngraminakg ideal body weight via a pump. After 10 min, at which time previous studies have shown a steady state concentration of adrenaline being attained, 10,11 indirect calorimetry was again performed for 20 min to calculate adrenaline-induced thermogenesis and RQ. Steady state metabolic rate was de®ned using minute to minute coef®cient of variatioǹ 10%. Plasma adrenaline was measured on completion of calorimetry. Aortic blood¯ow was again measured during the steady state of the adrenaline infusion.
Statistics
Results are presented as mean AE standard deviation unless otherwise stated. Comparability of the two groups was assessed by a 2-sample t test (Minitab Statistical Programme). Data which were not normally distributed were assessed by parametric tests if appropriate transformation was possible, but if not, the data were assessed by the Mann ± Whitney test. The relationship between change in energy expenditure and change in FFM and body weight were analysed by Spearman rank-correlation test for non-parametric data and by the Pearson method for parametric data. The difference between regression slopes for changes in REE and changes in FFM were calculated according to Armitage and Berry. 12 Tests were considered signi®cant at a P value`0.05.
Results
Ten subjects received sibutramine while nine received placebo. All nineteen subjects completed the study. No signi®cant adverse events were recorded in either group and compliance with medication was 100%, as assessed by patient self-report and by counting study medications. Of drugs which might affect results, bendro¯uazide was taken by one subject. The dose was unchanged during the study. Ultrasonographic measurements of cardiac output were obtainable in 12 subjects (6 sibutramine, 6 control). Other measurements were performed in all 19 subjects. The two groups were well matched in terms of body morphology, biochemistry, REE and adrenaline stimulated energy expenditure and haemodynamics (Table  1) .
Baseline mean plasma adrenaline concentration was 0.13 AE 0.01 nmolal. After 30 min infusion of adrenaline, a mean plasma concentration of adrenaline of 1.94 AE 0.50 nmolal was obtained. There was no difference in achieved adrenaline concentration between subjects on sibutramine compared to placebo (1.95 AE 0.66 nmolal vs 1.88 AE 0.62 nmolal, P`0.83). The mean rise of 1.81 nmolal in our subjects was similar to results obtained previously by Webber et al when using the same dose of adrenaline in a similar subject group. 13 There was no change in the mean noradrenaline concentration after the infusion. Plasma adrenaline measurements were unavailable for 4 subjects pre-treatment because of problems with sample storage, but we have included these earlier subjects in our overall analyses as they received the same infusion regime and their increases in heart rate were similar to the later volunteers.
In keeping with larger studies, the subjects who received sibutramine had greater weight loss and reduction in waist circumference than placebo (Table 2 ), but the numbers were not suf®cient to achieve signi®cance (P 0.13). There was a signi®-cant reduction in body fat mass (P 0.04). Reductions in fat-free mass and hip circumference were similar in the two groups. The decreases in serum insulin were not signi®cantly different, even when corrected for body weight.
After weight loss, REE fell in both groups. There was a suggestion that sibutramine blunted the adaptive decline in REE that occurs with weight loss compared to the subjects receiving placebo. This is shown when REE was expressed per kg body weight (P 0.31) and even more so when expressed per kg fat-free mass (P 0.11) which relates metabolic rate to the metabolically active tissues ( Table 3) . The difference between regression slopes for changes in REE and changes in FFM were initially calculated according to Armitage and Berry. 12 There was some suggestion that the usual positive correlation between loss of weight and decline in REE was lost in the sibutramine group (r 7 0.30) compared with placebo (r 0.35), P 0.095 (Figures 1a and 1b) . There was a signi®cant inverse correlation between change in REEakg FFM and change in FFM, r 7 0.66 (P 0.04), in subjects on sibutramine, which was not present in placebo subjects, r 7 0.04 (P 0.91) (Figures 2a and 2b) . The difference between these regression slopes for changes in REEakg FFM and changes in FFM using the Armitage and Berry method 12 was again suggestive of a treatment effect, P 0.08. Analysis of covariance (ANCOVA) which looked at the difference in intercept and difference in slope of the relationship between change in FFM and change in REE gave a P value for the difference in slopes of 0.094, which is also suggestive of a trend given the small sample numbers present. Using REEakg FFM instead of REE in the ANCOVA gave a similar P-value of 0.129.
Both groups had similar adrenaline-induced energy expenditure after weight loss, 1587 AE 211 kcala24 h on placebo and 1600 AE 113 kcala24 h on sibutramine subjects (P 0.88). When expressed per kg body weight, again there was no difference in adrenalineinduced thermogenesis, 19.72 AE 1.92 kcala24 hakg body weight in placebo and 18.83 AE 2.43 kcala 24 hakg body weight in sibutramine subjects (P 0.38). The percentage increase in REE during stimulation by adrenaline was 17.7 AE 8.7% in the placebo group and 11.1 AE 7.9% in the sibutramine group (P 0.10). 
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After weight loss, basal heart rate decreased in the placebo group by 5.4AE 7.2% while it increased in the sibutramine group by 3.1 AE 8.6% (P 0.035). The mean adrenaline-stimulated heart rate was similar in the two groups after the twelve week period, 76.9 AE 8.4 in the placebo group and 76.5AE 9.3 in the sibutramine group (P 0.93). The percentage increase in heart rate during stimulation by adrenaline was 16.6 AE 11.6% in the placebo group and 13.3AE 9.4% in the sibutramine group (P 0.51). The mean adrenaline-stimualted cardiac output was also similar in the two groups, 11 533AE 7168 mlamin in placebos and 9932 AE 5593 mlamin in the sibutramine group (P 0.69). The percentage increase in cardiac output during stimulation by adrenaline was 30.2 AE 44.3% in the placebo group and 50.5AE 32.0% in the sibutramine group (P 0.43).
Discussion
Several studies have investigated the effect of serotoninergic drugs on energy expenditure in humans. Most of the earlier studies found no effect of these agents on basal metabolic rate. 14 ± 16 Lafreniere et al found that RMR and postprandial thermogenesis (following a 400 kcal test meal) were similar in 15 obese subjects who received dexfen¯uramine 15 mg bd for three months and 15 obese subjects who receive placebo. 17 Recasens et al had similarly found no effect of dexfen¯uramine 30 mgad on RMR in twenty obese females; however, the 3 h thermic effect of food was increased. 18 Van Gaal et al studied the effect of dexfen¯uramine 30 mgad versus placebo for three months in 32 obese females. 19 When expressed per kg body weight, dexfen¯uramine limited the weight reduction-associated decrease in RMR while glucoseinduced thermogenesis (GIT) was increased in the ®rst hour. Scal® et al evaluated the effect of dexfen¯ur-amine in 7 obese males. 20 Dexfen¯uramine increased RMR and thermogenesis following a mixed test meal. There is a single report that¯uoxetine, a serotonin reuptake inhibitor, increases REE in obese females. 21 We have measured the effect of a 12 week course of sibutramine, a serotonin and noradrenaline reuptake inhibitor, on REE and adrenaline induced thermogenesis in 10 obese females and compared the results in 9 obese females receiving a placebo for the same period. Nordrenaline exerts its physiological effects mainly as a neurotransmitter 22 and its metabolic effects as a circulating hormone are only found with exceedingly high plasma concentrations, for example, during prolonged maximal exercise or severe illness like myocardial infarction. 22, 23 During hormone infusions, the plasma threshold concentration for cardiovascular and metabolic changes is about 10 times lower for adrenaline than for noradrenaline. 10, 22 Thus, it is impossible to mimic physiological events completely by noradrenaline infusions, and for these reasons adrenaline was chosen for the present study. The threshold for metabolic effects observed during adrenaline infusion in this experiment was well below the concentrations observed during ordinary activities like standing or mild exercise. 23, 24 Our data provide new evidence that sibutramine limits the decrease in REE which is normally associated with weight reduction. Indeed, REE was mildly increased, when adjusted for body weight or for lean body mass which re¯ects metabolically active tissues. There was a striking inverse correlation between decline in REakg FFM and decline in FFM in subjects on sibutramine which was not evident in placebo subjects. The usual positive correlation between loss of weight and decline in REE was lost in the sibutramine group (r 7 0.30) compared with placebo but the difference just failed to reach signi®cance (P 0.09) due to the small number of subjects studied. This rather complicated or unfamiliar analysis is demanded by the small effect in a multifactorial physiological system which requires a plot of change in REEaFFM against FFM itself. The analysis is analogous to plotting a change in speed (distanceatime) against time itself to demonstrate acceleration. These results support the suggestion of a thermogenic effect of sibutramine in humans from Hansen et al 25 and appear to indicate a well Sibutramine and energy expenditure KM Walsh et al maintained tonic action on the beta adrenoceptors in adipose tissue and other sites responsible for thermogenesis. 26 The value of this modest thermogenic effect is probably in long term weight maintenance rather than through any major effect on acute weight loss. Small mismatches between energy expenditure (EE) and energy intake (EI) can lead to large weight changes over time. An average man expends 1 000 000 kcalay. A mismatch between EE and EI of only 1%, that is, 10 000 kcalay, results in a gain of 1.5 kg of adipose tissue. The quantitative effect of sibutramine's action on REE can be estimated from data in Table 4 . Using these mean ®gures, following a weight loss of 5 ± 10% body weight, REE falls 9% in the placebo group and 5% in subjects on sibutramine. Taking the example of a 45 year old man of 90 kg body weight, at activity level 1.3ÂBMR his predicted 24 h EE would be 2500 kcalad. 27 His expected 24 h EE after weight loss on placebo would be 2275 kcalad (2500 less 9%). This is the amount of daily energy intake required to maintain his new weight on placebo. A similar patient who lost weight on sibutramine would be able to maintain the same new weight with an energy intake of 2375 kcalad (2500 less 5%). Thus he could maintain the same new weight despite consuming an extra 100 kcalad. Alternatively, if a 90 kg man reduces his energy intake to 2275 kcalad as before but while on sibutramine, the extra 100 kcalad drug effect would allow him to maintain a body weight of about 6 kg lower while on an identical energy intake to the man on placebo. Thus, patients who ®nd it dif®cult to maintain weight loss will be able to achieve this more easily while on sibutramine, as their energy intake can be increased without weight gain. Patients who are able to persevere with their reduced daily calorie intake will be rewarded with a decreased new weight level.
Sibutramine did not increase adrenaline-induced thermogenesis in this study. This is an assessment of the immediate thermogenic effect of adrenaline, and the data excluded augmentation by any trophic or other effect on the tissues responsible for thermogenesis. It would be interesting to look at its effect on a more prolonged thermogenic challenge following glucose or a test meal, especially a meal rich in carbohydrates, nutrients which have the most pronounced thermic effects. 28 It is possible that different results might have emerged if noradrenaline infusion had been used. It was reassuring to ®nd that sibutramine did not cause an excessive increase in heart rate and cardiac output in response to infusion of adrenaline. As shown previously, and in keeping with its mode of action, sibutramine increases basal heart rate in humans by a mean of 4 beatsaminute. 1 In summary, sibutramine had a favourable effect on energy expenditure in that it appeared to limit the adaptive decrease in REE that occurs with weight loss, but there was no effect on adrenaline-induced thermogenesis, when compared to placebo subjects. This effect on REE is unlikely to account for a great deal of the acute weight loss but could contribute to weight maintenance. 
